-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RpSYw5ynwFX4EU3+v3bIBfKsl5dsxO9DLfeGD/sskEgKUMXHD0YVTS2sYXozVFRi b9IDSDdZNzKM1LjsRz43ew== 0001201800-10-000133.txt : 20100901 0001201800-10-000133.hdr.sgml : 20100901 20100901161906 ACCESSION NUMBER: 0001201800-10-000133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100826 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20100901 DATE AS OF CHANGE: 20100901 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 101052675 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5169974600 MAIL ADDRESS: STREET 1: 150 MOTOR PARKWAY STREET 2: SUITE 408 CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 8-K 1 vaso8k-sept2010.htm vaso8k-sept2010.htm

Washington, D.C.
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report:  August 26, 2010
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File
(IRS Employer
of incorporation)
Identification No.)
180 Linden Avenue, Westbury, New York
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:                         (516) 997-4600
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
[ ]
Pre-commencement to communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c)



  Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
       Officers; Compensatory Arrangements of Certain Officers.
(b)           At a meeting held on August 26, 2010, the Board of Directors of the Company accepted the resignation of David Tarachand Singh as its Chief Financial Officer.
(c)            On August 26, 2010, the Board of Directors appointed Jonathan P. Newton as its Chief Financial Officer, effective September 1, 2010.  Mr. Newton replaces Dr. Jun Ma who was appointed in that capacity on an interim basis on August 26, 2010.   Mr. Newton will be compensated at the annual rate of $140,000 and will serve at the pleasure of the Board of Directors.  From June 2006 to August 2010, Mr. Newton was Director of Budgets and Financial Analysis for Curtiss-Wright Flow Control.   His responsibilities included the development of sophisticated financial forecasting models, preparing the annual budget, long-term strategic planning, cost analysis and SOX compliance.  From August 2001 to June 2006, Mr. Newton was Vasomedical’s Director of Budgets and Analysis.  In that capacity, his responsibilities included preparing annual budgets and forecasts, revenue, margin and cost analyses for management and the Company’s outside auditors, Board of Directors presentations, and preparation of the Company’s quarterly and annual SEC filings.  Prior positions included Controller of North American Telecommunications Corp,, Accounting Manager for Luitpold Pharmaceuticals, positions of increasing responsibility within the internal audit function of the Northrop Grumman Corporation and approximately three and one half years as an accountant for Deloitte Haskins & Sells, during which time Mr. Newton became a certified public accountant .  Mr. Newton holds a B.S. in Accounting from SUNY at Alb any, and a B.S. in Mechanical Engineering from Hofstra University.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:   September 1, 2010
By:   /s/ Jun Ma                                                        
Jun Ma
President and Chief Executive Officer